BACKGROUND Gastric cancer is a leading cause of cancer-related deaths worldwide.Prognostic assessments are typically based on the tumor-node-metastasis(TNM)staging system,which does not account for the molecular heter...BACKGROUND Gastric cancer is a leading cause of cancer-related deaths worldwide.Prognostic assessments are typically based on the tumor-node-metastasis(TNM)staging system,which does not account for the molecular heterogeneity of this disease.LATS2,a tumor suppressor gene involved in the Hippo signaling pathway,has been identified as a potential prognostic biomarker in gastric cancer.AIM To construct and validate a nomogram model that includes LATS2 expression to predict the survival prognosis of advanced gastric cancer patients following ra-dical surgery,and compare its predictive performance with traditional TNM staging.METHODS A retrospective analysis of 245 advanced gastric cancer patients from the Fourth Hospital of Hebei Medical University was conducted.The patients were divided into a training group(171 patients)and a validation group(74 patients)to deve-lop and test our prognostic model.The performance of the model was determined using C-indices,receiver operating characteristic curves,calibration plots,and decision curves.RESULTS The model demonstrated a high predictive accuracy with C-indices of 0.829 in the training set and 0.862 in the validation set.Area under the curve values for three-year and five-year survival prediction were significantly robust,suggesting an excellent discrimination ability.Calibration plots confirmed the high concordance between the predictions and actual survival outcomes.CONCLUSION We developed a nomogram model incorporating LATS2 expression,which significantly outperformed conven-tional TNM staging in predicting the prognosis of advanced gastric cancer patients postsurgery.This model may serve as a valuable tool for individualized patient management,allowing for more accurate stratification and im-proved clinical outcomes.Further validation in larger patient cohorts will be necessary to establish its generaliza-bility and clinical utility.展开更多
目的:研究CD59分子在LAT(Linker for activated T cells)介导的T系淋巴细胞活化中所起的作用。方法:构建LAT-GFP融合蛋白,以逆转录病毒为载体转染Jurkat细胞,建立稳定转染细胞株(Jurkat-GFP)。分别使用CD59抗体刺激和pSUPER-siCD59干扰...目的:研究CD59分子在LAT(Linker for activated T cells)介导的T系淋巴细胞活化中所起的作用。方法:构建LAT-GFP融合蛋白,以逆转录病毒为载体转染Jurkat细胞,建立稳定转染细胞株(Jurkat-GFP)。分别使用CD59抗体刺激和pSUPER-siCD59干扰质粒(GFP标记)沉默Jurkat-GFP细胞。免疫荧光观察CD59和LAT分子在细胞膜的表达和定位;MTT比色法检测细胞增殖率的变化;Western blot检测LAT活化信号转导通路中相关蛋白分子磷酸化水平。结果:荧光显微镜下可见Jurkat-GFP细胞绿色荧光表达于细胞膜,转染干扰质粒后细胞膜和细胞质均有绿色荧光表达。激光共聚焦显微镜下可见CD59抗体刺激前CD59和LAT分子均匀分布于细胞膜,且转染干扰质粒的Jurkat-GFP细胞CD59表达量下降。CD59抗体刺激后CD59分子和LAT分子点状聚集共定位于细胞膜。MTT结果表明相对于正常Jurkat-GFP细胞,抗体活化后细胞增殖速率明显升高(P>0.05),而电转干扰质粒后细胞生长减慢。Western blot结果表明,CD59抗体刺激后细胞ZAP-70、LCK、PLC-r总蛋白表达无明显差异(P>0.05),而磷酸化蛋白表达显著增高(P<0.05)。结论:抗体活化后细胞膜上CD59和LAT分子聚集并共定位于细胞膜,且细胞信号转导通路下游分子磷酸化水平增高,进一步证实CD59分子经抗体活化后可促进LAT介导的T细胞信号转导。展开更多
文摘BACKGROUND Gastric cancer is a leading cause of cancer-related deaths worldwide.Prognostic assessments are typically based on the tumor-node-metastasis(TNM)staging system,which does not account for the molecular heterogeneity of this disease.LATS2,a tumor suppressor gene involved in the Hippo signaling pathway,has been identified as a potential prognostic biomarker in gastric cancer.AIM To construct and validate a nomogram model that includes LATS2 expression to predict the survival prognosis of advanced gastric cancer patients following ra-dical surgery,and compare its predictive performance with traditional TNM staging.METHODS A retrospective analysis of 245 advanced gastric cancer patients from the Fourth Hospital of Hebei Medical University was conducted.The patients were divided into a training group(171 patients)and a validation group(74 patients)to deve-lop and test our prognostic model.The performance of the model was determined using C-indices,receiver operating characteristic curves,calibration plots,and decision curves.RESULTS The model demonstrated a high predictive accuracy with C-indices of 0.829 in the training set and 0.862 in the validation set.Area under the curve values for three-year and five-year survival prediction were significantly robust,suggesting an excellent discrimination ability.Calibration plots confirmed the high concordance between the predictions and actual survival outcomes.CONCLUSION We developed a nomogram model incorporating LATS2 expression,which significantly outperformed conven-tional TNM staging in predicting the prognosis of advanced gastric cancer patients postsurgery.This model may serve as a valuable tool for individualized patient management,allowing for more accurate stratification and im-proved clinical outcomes.Further validation in larger patient cohorts will be necessary to establish its generaliza-bility and clinical utility.
文摘目的:研究CD59分子在LAT(Linker for activated T cells)介导的T系淋巴细胞活化中所起的作用。方法:构建LAT-GFP融合蛋白,以逆转录病毒为载体转染Jurkat细胞,建立稳定转染细胞株(Jurkat-GFP)。分别使用CD59抗体刺激和pSUPER-siCD59干扰质粒(GFP标记)沉默Jurkat-GFP细胞。免疫荧光观察CD59和LAT分子在细胞膜的表达和定位;MTT比色法检测细胞增殖率的变化;Western blot检测LAT活化信号转导通路中相关蛋白分子磷酸化水平。结果:荧光显微镜下可见Jurkat-GFP细胞绿色荧光表达于细胞膜,转染干扰质粒后细胞膜和细胞质均有绿色荧光表达。激光共聚焦显微镜下可见CD59抗体刺激前CD59和LAT分子均匀分布于细胞膜,且转染干扰质粒的Jurkat-GFP细胞CD59表达量下降。CD59抗体刺激后CD59分子和LAT分子点状聚集共定位于细胞膜。MTT结果表明相对于正常Jurkat-GFP细胞,抗体活化后细胞增殖速率明显升高(P>0.05),而电转干扰质粒后细胞生长减慢。Western blot结果表明,CD59抗体刺激后细胞ZAP-70、LCK、PLC-r总蛋白表达无明显差异(P>0.05),而磷酸化蛋白表达显著增高(P<0.05)。结论:抗体活化后细胞膜上CD59和LAT分子聚集并共定位于细胞膜,且细胞信号转导通路下游分子磷酸化水平增高,进一步证实CD59分子经抗体活化后可促进LAT介导的T细胞信号转导。
